Types and clinical use of anti-HGF mAbs and multi-kinase inhibitors
| Drug | Type, target and references | Disease, stage and references |
|---|---|---|
| Ficlatuzumab/AV-299 | mAb against HGF90 | Solid tumours (Phase I/II), NSCLC (combined with gefitinib, Phase II).90 |
| Rilotumumab/AMG 102 | mAb against HGF90 | Multiple tumour types including: RCC (Phase II), prostate cancer (combined with mitoxantrone and prednisone, Phase II).91 92 |
| Onartuzumab/PRO143966 | mAb against Met93 | NSCLC (combination with erlotinib, Phase II), solid tumours (Phase I)94 95 |
| Cabozantinib/BMS-907351 | TKI of Met, VEGFR2, RET, Kit, AXL and FLT396 | Multiple tumour types including: prostate, breast cancer, NSCLC (Phase II)97 98 |
| Crizotinib/PF-02341066 | TKI of Met, ALK and ROS1 99 | NSCLC (Phase III), GEC (Phase I)99 100 |
| Tivantinib/ARQ 197 | TKI of Met101 | HCC (Phase II), NSCLC (Phase II), gastric cancer (Phase II)102–104 |
| Foretinib/GSK1363089 | TKI of Met, VEGFR2, RON, Kit and AXL105 | Gastric cancer (Phase II), solid tumours (Phase I)105 106 |
ALK, anaplastic lymphoma kinase; FLT3, FMS-like tyrosine kinase-3; GEC, gastroesophageal cancer; HCC, hepatocellular carcinoma; HGF, hepatocyte growth factor; NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma; RON, Recepteur d'Origine Nantais; VEGFR, vascular endothelial growth factor receptor; mAb, monoclonal antibody; TKI, tyrosine kinase inhibitors; RET, rearranged during transfection; ROS1, c-ros oncogene 1; Met, hepatocyte-derived growth factor receptor.